NewAmsterdam Reports Cholesterol Drug Obicetrapib May Slow Alzheimer’s Biomarker Buildup
NewAmsterdam Pharma announced positive results from a prespecified sub-study of its Phase 3 BROADWAY trial involving obicetrapib, a CETP inhibitor.
The sub-study focused on patients with cardiovascular disease or familial hypercholesterolemia and included analysis of Alzheimer’s disease plasma biomarkers.
The study found statistically significant reductions in the Alzheimer’s biomarker p-tau217 in both the overall trial population and ApoE4 carriers over 12 months.
The trial included 1,727 patients, with 367 carrying the ApoE4 gene variant.
Additional biomarkers monitored included neurofilament light chain and glial fibrillary acidic protein.
Full results will be presented at the Alzheimer’s Association International Conference in Toronto in July 2025.